MCL comprises 5% to 10% of NHL, characterized by genetic alterations involving p53, cyclin-dependent kinase (CDK) 4, CDKN2A, MYC, BCL-2, BCR, and nuclear factor (NF)-κB [146]. Here, TP53 is linked to non-Hodgkin lymphoma.